Accountability of governments, policy makers, regulators and the medical fraternity for failed COVID-19 policy measures and mandates

16 mins read
An in-depth letter, signed by healthcare professionals from around the world, calling for the accountability of those that ignored the warnings that the cost of Covid policy would have far-reaching consequences.

Having tried to contain the Covid-19 epidemic for two years, real-world evidence suggests that the measures adopted globally have failed in their primary objective of “controlling the virus”, whilst at the same time causing immense harm. Indeed, there is no compelling evidence supporting lockdown restrictions, social distancing, mask mandates or vaccine mandates.

As healthcare professionals we therefore demand:

1. An immediate halt to all Covid-19 mandates and, if deemed necessary, a switch to the use of purely voluntary measures such as those practised during  outbreaks of seasonal influenza.

2. An immediate review of policies and procedures adopted under the guise of the Covid-19 emergency measures.

3. An immediate review of the role of policymaking, regulatory bodies and task groups involved in Covid-19 policy recommendations and mandates.

4. The establishment of a process to hold accountable – where deemed appropriate –  those individuals and organizations involved in the promulgation, implementation and enforcement of Covid-19 policies, procedures and mandates.

When the Covid-19 pandemic was declared, many countries adopted a non-negotiable stance and enforced policies and medical management based on biased data distributed by limited sources from a select group of institutions. Despite a lack of solid supporting evidence, and despite significant internal discord within these institutions, governments, policy makers, regulators and medical advisors chose to follow and impose a single, unwavering narrative on their nations to the exclusion of any other viewpoints. This had devastating economic repercussions and has undermined trust in the medical profession.

The economic repercussions of the Covid-19 policies will be felt for years to come. The monetary costs of measures taken to prevent the spread of the virus have drastically outweighed the costs of the direct effects of the virus itself. The gap between economic classes has widened considerably, with a minority of select stakeholders enjoying great increases in wealth, while the majority of people experience economic decline.

A relationship of trust between doctor and patient should be at the core of Medicine. But, despite some physicians and medical groups having developed potentially effective early treatment protocols for Covid-19, using approved and well-established medicines, governments, policy makers, regulators and medical advisors chose to suppress and even criminalize any discussion of the use of these medicines in the management and care of patients. They also chose to enforce questionable medical protocols that, in some countries, may well have resulted in the unnecessary deaths of numerous individuals. This included possible over-prescribing of Midazolam for care-home patients in Britain, the inappropriate application of “Do Not Resuscitate” orders, and the use of Remdesivir and early intubation for hospital patients in the USA.

While effective early treatments were being suppressed, candidate mRNA ‘vaccines’ were rushed to market under emergency use authorization (EUA). Despite being inadequately tested, these novel and unconventional gene-based injections continue to be forced on populations through mandates and coercion. While they are constantly touted as ‘safe and effective’, it is clear that these injections are failing, with boosters now being required regularly and unprecedented numbers of adverse reactions – including deaths – being reported.

It is our contention that as a result of the aforementioned failures by governments, policy makers, regulators and medical advisors, considerably more overall harm to health – including many more deaths – have resulted than would have been the case had prior pandemic planning policies been followed.


The following two sections of this document present:

Section 1: A summary of what we now know about the Covid-19 epidemic, most of which has been suppressed by governments, corporations, international agencies and the media.

Section 2: A comprehensive list of references in which the evidence for these statements may be found.

This is the evidence upon which we base our demands for a halt to the Covid-19 measures, a thorough review of these measures, and the holding to account of those who have perpetrated and profited from these measures.


Section 1: The Covid-19 Situation, February 2022

According to evidence-based literature and comparative analysis we know the following:

Covid-19 Vaccines:

  1. Do not prevent viral transmission;
  2. Do not prevent infection; and
  3. Do not statistically reduce all-cause hospitalization or all-cause mortality.  Recent studies are reporting an increase in all-cause mortality in vaccinated groups.
  4. Short-term safety data to date are also extremely concerning, with unprecedented numbers of severe adverse reactions, including deaths, being reported in association with the injections.
  5. There is growing evidence that Covid-19 vaccines have negative effects on the immune system, including immunosuppression.
  6. The long-term safety profile and long-term adverse effects, especially from repeated doses and “boosters”, are as yet unknown and raise concern.

Natural immunity vs. vaccine-induced immunity:

  1. Natural immunity to SARS-CoV-2 is superior to immunity provided by vaccination, highly likely to be broader in scope (i.e. against future variants) and of longer duration.
  2. As such, administering the Covid-19 vaccinations to the Covid-recovered provides little to no benefit whilst exposing the recipient to known and unknown risks.
  3. Any recommendation that those who have already been infected with SARS-CoV-2 should receive the vaccine contradicts evidence-based medicine.
  4. Data shows that a level of community immunity has been reached in most places which is compatible with an endemic equilibrium state which, combined with less virulent variants and better treatment options, means that the time has come to “learn to live with Covid” and return to normality.

Therapeutic protocols and interventions in Covid-19 therapy:

  1. Multicentre reports provide evidence that early therapeutic intervention results in improved outcomes after Covid-19 infection.

The PCR test: 

  1. PCR tests that were mandated globally as a form of screening for Covid-19 produced a high percentage of operational false positive results.
  2. There was no basis for the widespread use of this test as a positive PCR test does not reliably signify infectiousness.
  3. The PCR test yields a particularly high percentage of false positive results in asymptomatic individuals. This is consistent with a previously well-known observation in epidemiology that tests performed on asymptomatic individuals have low positive predictive value.

Asymptomatic transmission:

  1. There is no evidence that asymptomatic people are significant drivers of transmission of SARS-CoV-2.
  2. There is no evidence that isolating asymptomatic people who have a positive PCR test for Covid-19 provides any benefit.

The risk of Covid-19 in children:

  1. Nearly all children infected with Covid-19 have very mild symptoms.
  2. Most children who test positive for Covid-19 are asymptomatic.
  3. There is no compelling data demonstrating that asymptomatic transmission or transmission of Covid-19 from children is a significant risk to healthy adults.
  4. Many other respiratory pathogens affect children to a higher degree than SARS-CoV-2.

Overreporting and exaggeration of Covid-19 deaths in hospital:

  1. There is evidence that hospitalization and mortality rates from Covid-19 have been grossly overestimated in most countries. This is due to basing estimates solely on PCR testing, while disregarding the etiology or cause of the clinical condition, comorbidities and grounds for admission to hospital.

Lockdown measures:

  1. The global lockdown of communities, including isolating healthy individuals, curfews, social distancing and mask mandates, have not been proven effective at reducing the risk of Covid-19 infection but have been shown to cause significant non-Covid harm; the stringency of lockdown measures was not correlated with reduced burden from Covid-19.

Based on the observations above, our demand to governments, policy makers, regulators and the medical fraternity is the immediate termination of all Covid-19 policies, including mandates, vaccine passports, segregation and discrimination based on an individual’s health or vaccination status.


Section 2: Reference list of supporting studies

We present a comprehensive summary of references supporting the summary of findings listed above.

COVID-19 Vaccines

  1. Piero Olliaro, Els Torreele, Michel Vaillant, COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room, The Lancet Microbe, Volume 2, Issue 7, 2021, Pages e279-e280,ISSN 2666-5247,
  3. Spiegelhalter D. Use of “normal” risk to improve understanding of dangers of COVID-19 BMJ 2020; 370 :m3259 doi:10.1136/bmj.m3259.
  4. Doshi P, Godlee F, Abbasi K. COVID-19 vaccines and treatments: We must have raw data, Now. BMJ 2022; 376 :o102 doi:10.1136/bmj.o102
  5. Abu-Raddad, L.J., Chemaitelly, H., Ayoub, H.H. et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Sci Rep 11, 6233 (2021).
  6. Reports of vaccine adverse events and COVID-19 vaccine reported mortality in VAERS.
  7. Sebastian Molina-Rios, Rigoberto Rojas-Martinez, Gloria Marcela Estévez-Ramirez, Yimy Francisco Medina, Systemic lupus erythematosus and antiphospholipid syndrome after COVID-19 vaccination. A case report, Modern Rheumatology Case Reports, 2022;, rxac018,
  8. Ana L Saraiva, Ana R Vieira, Maria C Marinho, Oksana Zadorozhnya, Varicella zoster virus reactivation following COVID-19 vaccination: a report of 3 cases, Family Practice, 2022;, cmac014,
  9. Moslemi, M., Ardalan, M., Haramshahi, M. et al. Herpes simplex encephalitis following ChAdOx1 nCoV-19 vaccination: a case report and review of the literature. BMC Infect Dis 22, 217 (2022).
  10. Seyed Farzad Maroufi, Fereshteh Naderi Behdani, Fatemeh Rezania, Samaneh Tanhapour Khotbehsara & Zahra Mirzaasgari (2022) Longitudinally extensive transverse myelitis after Covid-19 vaccination: case report and review of literature, Human Vaccines & Immunotherapeutics, 18:1, DOI: 10.1080/21645515.2022.2040239
  11. Masoud Etemadifar, Hosein Nouri, Mehri Salari & Nahad Sedaghat (2022) Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse, Human Vaccines & Immunotherapeutics, 18:1, DOI: 10.1080/21645515.2022.2033540
  12. Flannery P, Yang I, Keyvani M, Sakoulas G. Acute Psychosis Due to Anti-N-Methyl D-Aspartate Receptor Encephalitis Following COVID-19 Vaccination: A Case Report. Front Neurol. 2021 Nov 4;12:764197. doi: 10.3389/fneur.2021.764197.
  13. Munasinghe B, Fernando U, Mathurageethan M, Sritharan D. Reactivation of varicella-zoster virus following mRNA COVID-19 vaccination in a patient with moderately differentiated adenocarcinoma of rectum: A case report. SAGE Open Medical Case Reports. January 2022. doi:10.1177/2050313X221077737
  14. The Israeli Public Emergency Council for the COVID-19 Crisis. Position Paper. The Science and the Ethics Regarding the Risk Posed by Non-Vaccinated Individuals.
  15. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577.
  16. Olifaro, P. et al. COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room.
  19. Riemersma, KK. Et al. Shedding of Infectious SARS-CoV-2 Despite Vaccination. August 24, 2021
  20. Kasen K. Riemersma, Brittany E. Grogan et al. Shedding of Infectious SARS-CoV-2 Despite Vaccination doi:
  21. Classen, JB.  US COVID-19 Vaccines Proven to Cause More Harm than Good Based on Pivotal Clinical Trial Data Analyzed Using the Proper Scientific Endpoint, “All Cause Severe Morbidity”. Trends Int Med. 2021; 1(1): 1-6.
  22. Classen B. US COVID-19 Vaccines Proven to Cause More Harm than Good Based on Pivotal Clinical Trial Data Analyzed Using the Proper Scientific Endpoint, “All Cause Severe Morbidity”. Trends Int Med. 2021; 1(1): 1-6
  25. Vogel, G. (2021). Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. Science.
  26. Universal Declaration on Bioethics and Human Rights
  27. Subramanian, SV. Et al. Increases in COVID‑19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States. European Journal of Epidemiology. September, 2021.
  28. Delepine, G. Covid-19 Vaccines Lead to New Infections and Mortality: The Evidence is Overwhelming.
  29. Kampf, G. COVID-19: Stigmatising the unvaccinated is not justified. The Lancet. Vol 398:10314. P. 1871. November 20, 2021.
  30. Gundry, SR. Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning. 8 Nov 2021Circulation. 2021; 144: A10712.
  31. Salvatore, P. et al. Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021.
  32. Hirsh, H. Bradley, G. Covid-19 Vaccine Mandates Fail the Jacobson Test. November 30, 2021
  34. Kampf, G. The epidemiological relevance of the COVID-19-vaccinated population is increasing. The Lancet. November 19, 2021.
  35. Lyons-Weber, J. In the United States, Vaccination Rates Are Associated with Increased Rate of Spread of SARS-CoV-2, But Not How They Should Be.
  36. Beattie, K. Worldwide Bayesian Causal Impact Analysis of Vaccine Administration on Deaths and Cases Associated with COVID-19: A BigData Analysis of 145 Countries.
  37. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med 2021;384:2273-82. 2.
  38. Sun H. Adjustment is required to calculate the risk of early pregnancy loss with COVID-19 infection or vaccination. Am J Obstet Gynecol 2021 August 3 (Epub ahead of print). DOI: 10.1056/NEJMc2113516
  39. Zauche LH, Wallace B, Smoots AN, et al. Receipt of mRNA Covid-19 vaccines and risk of spontaneous abortion. N Engl J Med 2021;385:1533-5. DOI: 10.1056/NEJMc2113516

Summary statement for ref 29-31 – A study published in NEJM in June, 2021 declares COVID-19 vaccines as safe during pregnancy. Further revisions of this study and article published in November, 2021 demonstrate the limitations and errors of this study and show the high rate of spontaneous abortions in women exposed to the vaccine during their first trimester of pregnancy.

  1. Brock, A., & Thornley, S. (2021). Rapid Communication Spontaneous Abortions and Policies on COVID-19 mRNA Vaccine Use During Pregnancy.
  4. Notable and Emerging Variants of SARS-CoV-2 Virus: A Quick Glance
  5. Jacob Westerhout, Hamid Khataee, Zoltan Neufeld. Effect of vaccination rates on the prevalence and mortality of COVID-19.
  6. Christine S. Benn, Frederik Schaltz-Buchholzer, et al. Randomised clinical trials of COVID-19 vaccines: do adenovirus-vector vaccines have beneficial non-specific effects?
  7. Stephanie Seneff, Greg Nigh, Anthony M. Kyriakopoulos, Peter A. McCullough. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs, Food and Chemical Toxicology, Volume 164, 2022.

Natural immunity vs. vaccine-induced immunity

  1. Girardot, M. Natural immunity vs Covid-19 vaccine-induced immunity. June 28, 2021.
  2. O Murchu E, Byrne P, Carty PG, et al. Quantifying the risk of SARS‐CoV‐2 reinfection over time. Rev Med Virol. 2022;32(1):e2260. 226
  3. Radbruch A. et al. A long term perspective on immunity to COVID. Nature. Vol 595. July 15, 2021.
  4. Abu-Raddad, LJ. Et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. May 1, 2021. E Clinical Medicine 35 (2021) 100861.
  5. Haveri, A. et al. Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. European Journal of Immunology. September 27, 2021.
  6. Gazit, S et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. August 25, 2021.
  7. Shrestha, NK. Et al. Necessity of COVID-19 vaccination in previously infected individuals. August 24, 2021.
  8. Cohen, KW. Et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Reports Medicine. July 21, 2021
  9. Israel, A. et al. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. August 22, 2021
  10. Ivanova, Ellie and Devlin, et al. Discrete Immune Response Signature to SARS-CoV-2 mRNA Vaccination Versus Infection.
  11. Turner, J.S., Kim, W., Kalaidina, E. et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 595, 421–425 (2021).
  12. Jason Neidleman, Xiaoyu Luo, et al. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. DOI: 10.7554/eLife.72619
  13. Israel A, Shenhar Y, Green I, Merzon E, Golan-Cohen A, Schäffer AA, Ruppin E, Vinker S, Magen E. Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection. Vaccines. 2022; 10(1):64.
  14. Laith J. Abu-Raddad, Hiam Chemaitelly, Peter Coyle, et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. eClinicalMedicine, Volume 35, 2021,
  15. Yair Goldberg, Micha Mandel, Yonatan Woodbridge, et al. Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel.
  16. Nina Le Bert, Hannah E. Clapham, et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J Exp Med 3 May 2021; 218 (5) doi:
  17. Jung, J.H., Rha, MS., Sa, M. et al. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells. Nat Commun 12, 4043 (2021).
  18. Daniel Lozano-Ojalvo, Carmen Camara, Eduardo Lopez-Granados, et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals, Cell Reports, Volume 36, Issue 8, 2021,
  19. Redd AD, Nardin A, Kared H, et al. CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants. Open Forum Infect Dis. 2021 Mar 30;8(7):ofab143. doi: 10.1093/ofid/ofab143.
  20. Bonifacius, A. et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity. 54, 340-354, 2021.
  21. Doshi, P. (Ed). Covid-19: Do many people have pre-existing immunity? BMJ. 2020; 370:m3563
  22. Echeverría G. et al. Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay. International Journal of Infectious Diseases. (2021).
  23. Le Bert, N. et al. Different pattern of pre-existing SARS-COV-2 specific T cell immunity in SARS-recovered and uninfected individuals. (2020).
  24. Tarke A. et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Reports Medicine 2, February 16, 2021.
  25. Swadling, L. et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature (2021).

Therapeutic protocols and interventions in COVID-19 therapy

  1. Kory, Pierre et al. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. American Journal of Therapeutics: May/June 2021 – Volume 28:3:p e299-e318
  2. McCullough PA, Kelly RJ, Ruocco G, et al. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med. 2021;134(1):16-22.
  3. Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther. 2021;28(4):e434-e460.
  4. Fleming RM, Fleming MR. Is there a treatment for SARS-CoV-2? Quantitative Nuclear Imaging finds Treatments for SARS-CoV-2.. Research Square; 2020. DOI: 10.21203/
  5. Early Ambulatory Multidrug Therapy, McCullough et al:
  6. FMTVDM Quantitative Nuclear Imaging finds Three Treatments for SARS-CoV-2
  7. The I-MASK+ Early Outpatient Treatment Protocol for COVID-19:
  8. Zelenko Early Treatment Protocol:
  9. The Fleming Directed CoVid-19 Treatment Protocol (FMTVDM):
  10. ICON Protocol – (Ivermectin in Covid Nineteen):
  11. MATH+ Hospital Treatment Protocol
  12. Budesonide-focused Treatment Protocol: from
  13. Prophylaxis and Treatment for COVID-19 in Nursing Homes
  14. The following is the protocol Drs. Fareed and Tyson have jointly developed as most effective for their COVID-19 patients:
  15. The Medical Letter on Drugs and Therapeutics Treatments considered for COVID-19
  16. A Guide to Home-Based COVID Treatment. An educational resource from The Association of American Physicians and Surgeons (
  17. Doshi P, Godlee F, Abbasi K. Covid-19 vaccines and treatments: We must have raw data, Now. BMJ 2022; 376 :o102 doi:10.1136/bmj.o102

The PCR test

  1. The performance of the SARS-CoV-2 RT-PCR test as a tool for detecting SARS-CoV-2 infection in the population Andreas Stang, et al. Journal of Infection.
  2. The failure of PCR mass testing.
  3. Cohen, A. N., & Kessel, B. (2020, May 20). False positives in reverse transcription PCR testing for SARS-CoV-2.
  4. Cohen, A. N., & Kessel, B., Milgroom, M. (2020, August). Diagnosing COVID-19 infection: the danger of over-reliance on positive test results
  5. Surkova E. False Positive Results (2020).
  6. Bullard, J. et al. Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 from Diagnostic Samples. Clinical Infectious Diseases. 2020: 71 (15 November).
  7. Dahdouh, E. et al. Ct values from SARS-CoV-2 diagnostic PCR assays should not be used as direct estimates of viral load. Journal of Infection. 2020. October 24.
  8. Jaafar, R. Aherfi, S. Wurtz, N. Grimaldier, C Hoang, VT. Colson, P. Raoult, D. La Scola, B. Correlation Between 3790 Quantitative Polymerase Chain Reaction–Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates. Clinical Infectious Diseases. 29 September, 2020.
  9. Jefferson, T., & Heneghan, G. el al. (2020) Are you infectious if you have a positive PCR test for COVID-19?
  10. Santos, Chiesa. PCR Positives. What Do They Mean? (Sept. 2020)
  11. WHO. Information notice for IVD Users 2020/05 (2021).
  12. Gnomegen COVID-19 Digital PCR Detection Kit. Instructions for Use. P. 15.
  13. LBL-0109-04-900251-EUA-CE-Smart-Detect (P. 26).
  14. Corman-Drosten Review Report.
  15. Andreas Stang, Johannes Robers, Birte Schonert, Karl-Heinz Jöckel, Angela  Spelsberg, Ulrich Keil, Paul Cullen, The performance of the SARS-CoV-2 RT-PCR test as a tool for detecting SARS-CoV-2 infection in the population, Journal of Infection, Volume 83, Issue 2, 2021, Pages 237-279, ISSN 0163 4453,

Asymptomatic transmission

  1. Fauci, A.
  2. Patrozou, E. Mermel, LA. Does Influenza Transmission Occur from Asymptomatic Infection or Prior to Symptom Onset? Public Health Reports. 2009. Vol 124.
  3. Gao, M. et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. Respiratory Medicine 169 (2020) 106026.
  4. Madewell, Z. et al. Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. JAMA Network Open. 2020; 3(12).
  5. Pollock, AM., Lancaster, J. Asymptomatic Transmission of COVID-9. BMJ 2020;371
  6. Cao, S et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. Nature Communications. (2020) 11:5917.

The risk of COVID-19 in children

No increased paediatric COVID mortality

  1. Odd D, Stoianova S, Williams T, et al. Child mortality in England during the COVID-19 pandemic Archives of Disease in Childhood Published Online First: 21 June 2021. doi:10.1136/archdischild-2020-320899

COVID is a mild disease in children

  1. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Götzinger et al. Lancet Child Adolesc Health 2020; 4: 653–61
  2. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Molteni et a;. Lancet Child Adolesc Health 2021.
  3. Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden (Letter to Editor). Jonas F. Ludvigsson. N Engl J Med 384;7   DOI:10.1056/NEJMc2026670
  4. Sharing a household with children and risk of COVID-19: a study of over 300 000 adults living in healthcare worker households in Scotland. Wood R, et al. Arch Dis Child 2021;0:1–6. doi:10.1136/archdischild-2021-321604
  5. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). Cui X, Zhao Z, Zhang T, Guo W, Guo W, Zheng J, Zhang J, Dong C, Na R, Zheng L, Li W, Liu Z, Ma J, Wang J, He S, Xu Y, Si P, Shen Y, Cai C. J Med Virol. 2021 Feb;93(2):1057-1069. doi: 10.1002/jmv.26398. Epub 2020 Sep 28. PMID: 32761898; PMCID: PMC7436402
  6. Yasuhara J, Kuno T, Takagi H, Sumitomo N. Clinical characteristics of COVID-19 in children: A systematic review. Pediatr Pulmonol. 2020 Oct;55(10):2565-2575. doi: 10.1002/ppul.24991. Epub 2020 Aug 4. PMID: 32725955.
  7. de Souza, TH, Nadal, JA, Nogueira, RJN, Pereira, RM, Brandão, MB. Clinical manifestations of children with COVID-19: A systematic review. Pediatric Pulmonology. 2020; 55: 1892– 1899.
  8. Bai, Y, Gao, L, Wang, X, Zhong, L, Li, J, Ding, S, et al. Epidemiological characteristics and clinical manifestations of pediatric patients with COVID-19 in China: A multicenter retrospective study. Pediatr Invest. 2021; 5: 203- 210.
  9. Alsohime F, Temsah MH, Al-Nemri AM, Somily AM, Al-Subaie S. COVID-19 infection prevalence in pediatric population: Etiology, clinical presentation, and outcome. J Infect Public Health. 2020 Dec;13(12):1791-1796. doi: 10.1016/j.jiph.2020.10.008. Epub 2020 Oct 20. PMID: 33127335; PMCID: PMC7574780.
  10. Chinese Center for Disease Control and Prevention. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) – China, 2020. China CDC Wkly 2020;2(8):113–22. Available from: Article-COVID-19.pdf.
  11. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020 Jun;109(6):1088-1095. doi: 10.1111/apa.15270. Epub 2020 Apr 14. PMID: 32202343; PMCID: PMC7228328.
  12. Ladhani SN, Amin-Chowdhury Z, Davies HG, Aiano F, Hayden I, Lacy J, Sinnathamby M, de Lusignan S, Demirjian A, Whittaker H, Andrews N, Zambon M, Hopkins S, Ramsay ME. COVID-19 in children: analysis of the first pandemic peak in England. Arch Dis Child. 2020 Dec;105(12):1180-1185. doi: 10.1136/archdischild-2020-320042. Epub 2020 Aug 12. PMID: 32796006; PMCID: PMC7431771.
  13. Rajapakse N, Dixit D. Human and novel coronavirus infections in children: a review. Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25. PMID: 32584199.

Maternal and Neonatal systemic review and meta-analysis

  1. Di Toro F, Gjoka M, Di Lorenzo G, De Santo D, De Seta F, Maso G, Risso FM, Romano F, Wiesenfeld U, Levi-D’Ancona R, Ronfani L, Ricci G. Impact of COVID-19 on maternal and neonatal outcomes: a systematic review and meta-analysis. Clin Microbiol Infect. 2021 Jan;27(1):36-46. doi: 10.1016/j.cmi.2020.10.007. Epub 2020 Nov 2. PMID: 33148440; PMCID: PMC7605748.

Children with disabilities in the United States and the COVID-19 pandemic

  1. Houtrow, Amy et al. Children with Disabilities in the United States and the COVID-19 Pandemic. 1 Jan. 2020 : 415 – 424

Children with other diseases and COVID

  1. Kaya Akca U, Atalay E, Cuceoglu MK, et al. Impact of the COVID-19 pandemic on the frequency of the pediatric rheumatic diseases [published online ahead of print, 2021 Nov 2]. Rheumatol Int. 2021;1-7. doi:10.1007/s00296-021-05027-7

Rare Multisystem inflammatory syndrome in children and SARS-CoV-2

  1. Panigrahy N, Policarpio J, Ramanathan R. Multisystem inflammatory syndrome in children and SARS-CoV-2: A scoping review. J Pediatr Rehabil Med. 2020;13(3):301-316. doi: 10.3233/PRM-200794. Erratum in: J Pediatr Rehabil Med. 2021;14(1):137. PMID: 33252101.

Overreporting and exaggeration of COVID-19 deaths in hospital

  2. Vital Statistics Reporting Guidance. Guidance for Certifying Deaths Due to Coronavirus Disease 2019 (COVID–19). Report No. 3. April 2020.
  3. McGowan, J. Are COVID Death Rates Comparing Apples and Oranges? Mathematical Software. January 25, 2021.

Lockdown measures

The global lockdown of communities, isolating healthy individuals, curfew, social distancing, and mask mandates have not been shown to provide any meaningful reduction in the burden of COVID infection.

  1. AIER (American Institute of Economic Research). Lockdowns Do Not Control the Coronavirus: The Evidence.
  2. COVID-19 Alternative Strategy: A Case for Health and Socioeconomic Wellbeing (2020).
  4. Chaudhry, R. et al. A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes. E Clinical Medicine 25 (2020) 100464.
  5. Great Barrington Declaration:
  6. Johnston, L. UK lockdown was a ‘monumental mistake’ and must not happen again – Boris scientist says (2020).
  7. Kulldorff, M. American Institute of Economic Research (2020).
  8. McClintock, T. Lockdowns are killing us. Mountain Democrat. February, 2021.
  9. Meunier, T. Full lockdown policies in Western Europe countries have no evident impacts on the COVID-19 epidemic (2020).
  10. Norway ‘could have controlled infection without lockdown’: health chief.
  11. Schneider, P. Canadian Health Expert: Cost of Lockdowns are at least 10 times higher than benefits. January 15, 2021.
  12. Jones N R, Qureshi Z U, Temple R J, Larwood J P J, Greenhalgh T, Bourouiba L et al. Two metres or one: what is the evidence for physical distancing in covid-19? BMJ 2020; 370 :m3223 doi:10.1136/bmj.m3223
  13. PANDA:
  14. PANDA. Protocol for Reopening Society. December, 2020.
  15. The Evidence which Suggests that This Is No Naturally Evolved Virus A Reconstructed Historical Aetiology of the SARS-CoV-2 Spike Birger Sørensen, Angus Dalgleish & Andres Susrud
  16. Unusual Features of theSARS-CoV-2Genome Suggesting Sophisticated Laboratory Modification Rather Than Natural Evolution and Delineation of Its Probable Synthetic Route
  17. The Fauci/COVID-19 Dossier
  21. Nicole Shu Ling Yeo-Teh & Bor Luen Tang (2021) An alarming retraction rate for scientific publications on Coronavirus Disease 2019 (COVID-19), Accountability in Research, 28:1, 47-53, DOI: 10.1080/08989621.2020.1782203
  22. Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020,
  23. Might SARS-CoV-2 Have Arisen via Serial Passage through an Animal Host or Cell Culture? A potential explanation for much of the novel coronavirus’ distinctive genome Karl Sirotkin
  24. Richard M Fleming
  25. by Jeffrey A Tucker
  26. Association of American Physicians and Surgeons. Mask Facts. September 2020.
  27. Bundgaard, H., Bundgaard, JS. Effectiveness of Adding a Mask Recommendation to other Public Health Measures to Prevent SARS-CoV-2 Infections in Danish Mask Wearers. Annals of Internal Medicine. 2020 Nov 18.
  28. Meehan, J. An Evidence Based Scientific Analysis of Why Masks are Ineffective, Unnecessary, and Harmful. November, 2020.
  30. Swiss Policy Research: Are Face Masks Effective? The Evidence (October 25, 2020).
  31. Xiao, J. et al. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings—Personal Protective and Environmental Measures. CDC Policy Review. Vol 26:5. May, 2020
  32. WHO. Mask use in the context of COVID-19. Interim guidance. 1 December 2020.
  33. Horowitz, D. Comprehensive analysis of 50 states shows greater spread with mask mandates.
  34. Rosner, E. Adverse Effects of Prolonged Mask Use among Healthcare Professionals during COVID-19. Journal of Infectious Disease Epidemiology. 2020, 6:130.
  35. Kisielinski K, Giboni P, Prescher A, Klosterhalfen B, Graessel D, Funken S, Kempski O, Hirsch O. Is a Mask That Covers the Mouth and Nose Free from Undesirable Side Effects in Everyday Use and Free of Potential Hazards? Int J Environ Res Public Health. 2021 Apr 20;18(8):4344. doi: 10.3390/ijerph18084344.
  36. MacIntyre, C Raina et al. “A cluster randomised trial of cloth masks compared with medical masks in healthcare workers.” BMJ open vol. 5,4 e006577. 22 Apr. 2015, doi:10.1136/bmjopen-2014-006577
  37. Schwarz, S. et al. Corona children studies “Co-Ki”: First results of a Germany-wide registry on mouth and nose covering (mask) in children.
  38. Techasatian, L. et al. The Effects of the Face Mask on the Skin Underneath: A Prospective Survey During the COVID-19 Pandemic. Journal of Primary Care and Community Health. 2020. 11: 1-7.
  39. Dingwall, R. COVID Science and Politics – the Case of Face Masks.
  40. Guerra, DD and Guerra, DJ. Mask mandate and use efficacy for COVID-19 containment in US States. International Research Journal of Public Health (2021), 5:55.
  41. Alexander, PE. The CDC’s Mask Mandate Study: Debunked.
  42. Members of EU Parliament oppose mask mandates.


In signing this letter as a registered healthcare professional, I call on governments and institutions to halt the Covid-19 measures, thoroughly review them, and hold to account those who have perpetrated and profited from these measures.


Publisher’s note: The opinions and findings expressed in articles, reports and interviews on this website are not necessarily the opinions of PANDA, its directors or associates.

Share this article


By entering your email address and clicking “Submit,” you agree to receive updates from PANDA about our work. To learn more about how we use and protect your personal data, please view our privacy policy.
Scroll to Top


As a non-profit organisation, PANDA’s work remains free of bias and conflicts of interest. Support our work with a monthly donation which aids our planning and resources, and enables societies that are healthy, functioning and resilient.. We rely on your financial support to keep the conversation open.

We value your privacy

We use cookies and similar technologies to improve your experience of our website, to collect anonymous statistics, and to keep our site reliable and secure.By clicking “Accept,” you consent to the use of cookies on this site. For more information, see our privacy policy.

We Rely On Your Financial Support

Every donation, big or small, will help us continue to discover, explore, plan, reach and impact more. Donate and be a part of Panda.